Share on StockTwits

NxStage Medical (NASDAQ:NXTM) SVP Winifred L. Swan unloaded 2,500 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $13.60, for a total value of $34,000.00. Following the sale, the senior vice president now directly owns 20,188 shares in the company, valued at approximately $274,557. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

NXTM has been the subject of a number of recent research reports. Analysts at Piper Jaffray raised their price target on shares of NxStage Medical from $16.00 to $18.00 in a research note on Friday, August 8th. Analysts at Canaccord Genuity raised their price target on shares of NxStage Medical from $19.00 to $20.00 in a research note on Friday, August 8th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $18.25.

Shares of NxStage Medical (NASDAQ:NXTM) traded up 2.42% during mid-day trading on Monday, hitting $13.53. 195,593 shares of the company’s stock traded hands. NxStage Medical has a one year low of $8.77 and a one year high of $15.65. The stock has a 50-day moving average of $13.63 and a 200-day moving average of $13.2. The company’s market cap is $836.5 million.

NxStage Medical (NASDAQ:NXTM) last announced its earnings results on Thursday, August 7th. The company reported ($0.12) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.11) by $0.01. The company had revenue of $74.10 million for the quarter, compared to the consensus estimate of $70.52 million. During the same quarter in the prior year, the company posted ($0.06) earnings per share. The company’s quarterly revenue was up 13.3% on a year-over-year basis. Analysts expect that NxStage Medical will post $-0.45 EPS for the current fiscal year.

NxStage Medical, Inc (NASDAQ:NXTM) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.